Adverse effects may occur when patients with air in the pleural space or in the cerebral ventricles breathe nitrous oxide. We developed an animal model to learn whether similar adverse effects are associated with the inhalation of nitrous oxide when air is present in the subcutaneous space. We induced extensive subcutaneous emphysema in swine and measured oxygen and carbon dioxide tensions in systemic arterial and mixed venous blood; cardiac output; intravaseular, airway, and pre-sternal subcutaneous pressures; total pulmonary-thoracic static compliance; and thoracic girth before and after a 45 minute period of breathing 75 per cent nitrous oxide in oxygen. Cardiac output decreased from 3.13 ---0.51 I/min to 2.40 -+ 0.62 l/rain (p < 0.05); no other values changed significantly. No significant adverse cardiorespiratory effects resulted from the transfer of inhaled nitrous oxide to the subcutaneous space in this animal model. KEY WORDS: ANAESTHETICS, GASES, nitrous oxide; COMPLICATIONS, subcutaneous emphysema.
induced by nitrous oxide in swine with subcutaneous emphysema.
METHODS
Ten young swine weighing 20-25 kg were anaesthetized with intramuscular ketamine hydrochloride 20 mg-kg -I. A catheter for the administration of fluids and drugs was inserted into a vein of the ear, the trachea was intubated and anaesthesia and immobilization were maintained with intravenous thiamylal and pancuronium bromide. The lungs were ventilated with air from a time-cycled volume ventilator, maintaining Pact2 between 4.9 and 5.7 kPa (37 and 43 ton). Body temperature was monitored by a pulmonary artery thermistor and was maintained at 37.0 ---I~ by external infrared heating. A Swan-Ganz | thermodilution catheter was placed into the pulmonary artery through a high cervical jugular venous cutdown. Each animal received lactated Ringer's solution, 2-3 ml.kg-I/hour to maintain hydration.
An 18-gauge Teflon | catheter was placed surgically into the carotid artery and a 12-gauge plastic catheter was placed into the subcutaneous tissue anterior to the sternum. Pressures from the arterial and central venous catheters, from the subcutaneous space and from the airway were transduced with a high fidelity pressure measurement (Bentley Laboratories, Inc., Irvine, 435 Can. Anaesth. Soc. J., vol. 29, no. 5, Septemb~: 1982 California) and recording system (Grass Medical Instruments, Quincy, Massachusetts).
Blood samples and measurements were obtained as follows: sampling of systemic and mixed venous (pulmonary arterial) blood for analysis of oxygen and carbon dioxide tensions; measurement of cardiac output (in triplicate) by the technique of thermodilution; measurement of vascular, pre-sternal subcutaneous and airway pressures during three consecutive respiratory cycles; determination of total pulmonarythoracic static compliance at three different volumes (functional residual capacity plus 250, 500 and 750 ml respectively) by means of a "super syringe"; and measurement of thoracic gkth at mid-sternum. Pulmonary shunt fraction (Qsp/Qt) was calculated using the equation
where Cam = 1.34 (hgb) (Sao,) + 0.0031 Pao~, C%~ = 1.34 (hgb) (S%~) + 0.0031 P%2, and Cc'o2 = 1.34 (hgb) (Sc%) + 0.003I (PB -Pa2o) FIo~ -Paco2 Saturations of haemoglobin in arterial, pulmonary arterial, and pulmonary end-capillary blood are Sam, S%2 and Sc%, respectively, and PB is barometric pressure. The respiratory quotient was assumed equal to 1; 1.34 is the oxygencarrying capacity of haemoglobin in mi 02/gm hgb, and 0.0031 is the oxygen solubility coefficient in mi 02/torr. Saturation of oxygen was calculated using the method described by Severinghaus. 7 We assumed Pc% to equal the calculated PAo2, Mean pulmonary-thoracic static compliance (CLT) was calculated using the equation, where APx is the change in airway pressure induced by the mechanically delivered tidal volume "x" in ml.
To produce diffuse bilateral thoracic subcutaneous emphysema, 1200 mi of air were injected slowly (2 rain) through the catheter into the pre-sternal space. After a 10 minute period of equilibration, control measurements were obtained. The animals were then ventilated with a volume ventilator with 75 per cent nitrous oxide with oxygen for 45 minutes; the concentration of inspired oxygen was monitored continuously CANADIAN ANAESTHETISTS' SOCIETY JOURNAL with an in-line oxygen analyzer, All measurements except cardiac output were repeated every ten minutes until the end of the observation period. Cardiac output was measured at the end of the 45 minute period. After final measurements, the animals were sacrificed by intravenous injection of potassium chloride and chest roentgenograms were obtained.
The Student t-test for paired data was used to assess the significance of the differences between means before and after exposure to nitrous oxide. All data are reported as means ---one standard deviation. The minimal level chosen for significance was p < 0.05.
RESULTS
Post-mortem chest roentgenograms confirmed the clinical impression of diffuse bilateral thoracic subcutaneous emphysema and documented the absence of pneumothorax and pneumomediastinum in each animal (Figure 1 ).
There was no significant change in Paco~; in Qsp/Qt; in subcutaneous, vascular, and peak airway pressures; in thoracic girth; or in lungthorax compliance after the inhalation of nitrous oxide for 45 minutes (Table I) . Cardiac output decreased from 3.13 ---0,51 l/min to 2.40 --. 0.62 l/min (p < 0.05) after ventilation with nitrous oxide for 45 minutes but, when measured again later in four of the animals, had returned to baseline within 10 minutes of discontinuing the nitrous oxide.
FmURE 1 To produce diffuse, bilateral thoracic subcutaneous emphysema (arrows), 1200ml of air were injected subcutaneously anterior to the sternum. 
DISCUSSION
We studied swine because their skin and subcutaneous tissue resemble those of humans. 8 A total volume of 1200 ml (48-60 ml.kg -I) of air was chosen for subcutaneous injection because unpublished pilot studies showed that that amount of air produced a physical and radiographic lesion similar to that observed in patients with extensive subcutaneous emphysema. We studied isolated subcutaneous emphysema (i.e., without concomitant pneumomediastinum or pneumothorax) to eliminate the potential confounding effects of pneumothorax and pneumomediastinum. Previous studies of the rate of movement of nitrous oxide into air-containing colon, small intestine, stomach, pleural space, and cerebral ventricle revealed approximate half-times for equilibration of 1130 minutes, 95 minutes, 75 minutes, 15 minutes, and six minutes, respectively. 2 Based on these equilibration times, we arbitrarily chose a 45 minute period of observation as one likely to reveal clinically significant changes in the variables of interest if they were going to occur.
Because of its low blood:gas solubility coefficient, nitrous oxide rapidly saturates highly peffused organs such as the heart and the brain. Equilibration in skin and fat occurs more slowly, but uptake of the drug by these tissues which enclose the subcutaneous space should be substantial within 45 minutes so that further transfer of nitrous oxide into the subcutaneous space should be minimal.
Our failure to find an increase reflected by thoracic girth in the volume of subcutaneous gas after the inhalation of nitrous oxide may be explained in two ways. First, the fatty interface between the subcutaneous tissue and the gas contained within it is relatively avascular so that, 23 in contrast to the tissues of the l?leural space, ' the ~ut, 2 the cerebral ventricles" and the middle ear,-the rate of transfer of gas to the subcutaneous tissue may be slower. Secondly, substantial quantities of nitrous oxide may have entered the lax subcutaneous space, but spread so easily cephalad or caudad that no measurable change occurred in thoracic girth.
Since no other measured values changed significantly, it is reasonable to assume that the decrease in cardiac output after 45 minutes of ventilation with 75 per cent nitrous oxide was caused by nitrous-oxide-induced myocardial depression, which is known to occur in swine, to In summary, we found no significant adverse cardiorespiratory effects associated with nitrous oxide inhalation in an animal model of subcutaneous emphysema. The concern articulated by Munson I and Rosenberg et al. s that inhalation of nitrous oxide by subjects with subcutaneous emphysema would be associated with adverse effects is not supported.
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